Claims for Patent: 5,716,643

Summary for Patent: 5,716,643

Title:	Large scale production of medicine coated crosslinked protein microspheres
Abstract:	A method and apparatus for large scale production of a product of in vivo medicine carriers which are medicine coated crosslinked protein microspheres for medicine administration. The reagents are prepared in solution and contained in respective bags. A series pumps and mixing chambers are connected to the reagent bags. The pumps are set at pre-determined rates and activated in a predetermined sequence within respective pre-determined delay periods, to achieve instantaneous component mixing and controlled sequential mixing characteristics.
Inventor(s):	Yen; Richard C. K. (Yorba Linda, CA)
Assignee:	Hemosphere Inc. (Irvine, CA)
Application Number:	08/487,303
Patent Claims:	1. A method for large scale production of a product of in vivo medicine carriers for medicine administration, comprising the steps of: a. assembling a large scale production system including: i) a first reagent unit including a first reagent bag and a first pump connected downstream from said first reagent bag; ii) a second reagent unit including a second reagent bag and a second pump connected downstream from said second reagent bag; iii) a third reagent unit including a third reagent bag and a third pump connected downstream from said third reagent bag; iv) a fourth reagent unit including a fourth reagent bag and a fourth pump connected downstream from said fourth reagent bag; v) a fifth reagent unit including a fifth reagent bag and a fifth pump connected downstream from said fifth reagent bag; vi) a sixth reagent unit including a sixth reagent bag and a sixth pump connected downstream from said sixth reagent bag; vii) a first mixing chamber connected downstream from said first, second and third pumps; viii) a second mixing chamber connected downstream from said fourth pump and said first mixing chamber; ix) a third mixing chamber connected downstream from said fifth pump and said second mixing chamber; x) a fourth mixing chamber connected downstream from said sixth pump and said third mixing chamber; xi) a first delay coil connected between said first and second mixing chambers; xii) a second delay coil connected between said second and third mixing chambers; xiii) a third delay coil connected between said third and fourth mixing chambers; xiv) a rinse fluid collection bag connected to said fourth mixing chamber via a first valve means; xv) a product collection bag also connected to said fourth mixing chamber via a second valve means; and xvi) connection robings interconnecting said reagent bags, pumps, mixing chambers, valves and collection bags; b. sterilizing said large scale production system; c. preparing a suitable rinse solution and respective solutions of a group of reagents including an albumin, a surfactant, an alcohol, a cross-linking agent, a medicine and a post-treatment agent, and i) filling said first reagent bag with said rinse solution; ii) filling said second reagent bag with a prepared solution of said albumin and said surfactant; iii) filling said third reagent bag with a prepared solution of said alcohol; iv) filling said fourth reagent bag with a prepared solution of said cross-linking agent; v) filling said fifth reagent bag with a prepared solution of said medicine; and vi) filling said sixth reagent bag with a prepared solution of said post-treatment agent; d. setting respective pump rates of said pumps for mixing pre-determined amounts of said reagents; e. activating said first pump to rinse said mixing chambers, delay coils and connection tubings with said rinse solution from said first reagent bag, and opening said first valve means to collect said rinse solution in said rinse fluid collection bag; f. deactivating said first pump, closing said first valve means and opening said second valve means such that said production collection bag is ready for collecting said product; g. activating said pumps in sequence for mixing said reagents in a predetermined order within a pre-determined time period to produce said product, including: i) activating said second pump to send said solution of said albumin and surfactant from said second reagent bag to said first mixing chamber, and as soon as said solution of said albumin and surfactant from said second reagent bag reaches said first mixing chamber, activating said third pump to send said solution of said alcohol from said third reagent bag to said first mixing chamber, to thereby mix in said first mixing chamber said solutions of said albumin and surfactant from said second reagent bag with said solution of said alcohol from said third reagent bag, resulting in a solution containing turbid suspension of monodispersed albumin microspheres; ii) after a first delay period determined by said first delay coil during which said solution of turbid suspension reaches from said first mixing chamber to said second mixing chamber, activating said fourth pump to send said solution of said cross-linking agent from said fourth reagent bag to said second mixing chamber, to thereby mix in said second mixing chamber said solution of turbid suspension from said first mixing chamber with said solution of said cross-linking agent from said fourth reagent bag, resulting in a solution of partially cross-linked albumin microspheres; iii) after a second delay period determined by said second delay coil during which said solution of partially cross-linked microspheres reaches from said second mixing chamber to said third mixing chamber, activating said fifth pump to send said solution of said medicine from said fifth reagent bag to said third mixing chamber, to thereby mix in said third mixing chamber said solution of partially cross-linked microspheres from said second mixing chamber with said solution of said medicine from said fifth reagent bag, resulting in a solution of partially cross-linked, monodispersed and medicine-coated albumin microspheres; and iv) after a third delay period determined by said third delay coil during which said solution of medicine-coated microspheres reaches from said third mixing chamber to said fourth mixing chamber, activating said sixth pump to send said solution of said post-treatment agent from said sixth reagent bag to said fourth mixing chamber, to thereby mix in said fourth mixing chamber said solution of medicine coated microspheres from said third mixing chamber with said solution of said post-treatment agent from said sixth reagent bag, resulting in said product which is a solution of cross-linked, monodispersed and medicine coated albumin microspheres; h. collecting said product in said product collection bag; i. after a desired amount of said product is collected, closing said second valve means, and deactivating said pumps in sequence to prevent aggregation in said product, including: i) first deactivating said third pump to stop sending said alcohol from said third reagent bag into said first mixing chamber; ii) after said first delay time, deactivating said fourth pump to stop sending said cross-linking agent from said fourth reagent bag into said second mixing chamber; iii) after said second delay time, deactivating said fifth pump to stop sending said medicine from said fifth reagent bag into said third mixing chamber; and iv) after said third delay time, deactivating said sixth pump to stop sending said post-treatment agent from said sixth reagent bag into said fourth mixing chamber; and j. as soon as said third pump is deactivated, activating said first pump to rinse said mixing chambers, delay coils and connection tubings again with said rinse solution from said first reagent bag, rinsing residuals of said product from said mixing chambers, delay coils and connection tubings into said product collection bag; k. whereby said large scale production method produces said product of cross-linked, monodispersed and medicine coated albumin microspheres which are useful as in vivo medicine carriers for medicine administration. 2. The method as defined in claim 1 wherein said step of preparing said solutions further includes the step of dilution. 3. The method as defined in claim 1 wherein said step of preparing said solutions further includes the step of filtration. 4. The method as defined in claim 1 wherein said rinse solution is normal saline. 5. The method as defined in claim 1 wherein said albumin is human serum albumin. 6. The method as defined in claim 1 wherein said surfactant is sodium tetradecyl sulfate. 7. The method as defined in claim 1 wherein said alcohol is ethanol. 8. The method as defined in claim 1 wherein said cross-linking agent is selected from a group consisting of glutaraldehyde, glutathione, sodium sulfite, sodium bisulfite, nicotinamide adenine dinucleotide phosphate, dithiothreitol, polyethylene glycol, 2-mercaptoethanol, 1-ketoglutaric acid, gamma-aminolevulinic acid, N-acetylneuraminic acid, DL lactic acid, thioctic acid, succinic acid, ascorbic acid, stannous chloride, manganese chloride, magnesium chloride, gentamycin, poly-l-lysine, cysteine and dimethyl sulfoxide. 9. The method as defined in claim 1 wherein said medicine is fibrinogen. 10. The method as defined in claim 1 wherein said post-treatment agent is dextrose. 11. A device produced by the method as defined in claim 1. 12. A method for large scale production of a product of in vivo medicine carriers, comprising the steps of: a. assembling a large scale production system including: i) a protein unit including a protein bag and a protein pump connected downstream from said protein bag; ii) an alcohol unit including an alcohol bag and an alcohol pump connected downstream from said alcohol bag; iii) a cross-linking agent unit including a cross-linking agent bag and a cross-linking agent pump connected downstream from said cross-linking agent bag; iv) a medicine unit including a medicine bag and a medicine pump connected downstream from said medicine bag; v) a first mixing chamber connected downstream from said protein and alcohol pumps; vi) a second mixing chamber connected downstream from said cross-linking agent pump and said first mixing chamber; vii) a third mixing chamber connected downstream from said medicine pump and said second mixing chamber; viii) a first delay means connected between said first and second mixing chambers; ix) a second delay means connected between said second and third mixing chambers; x) a product collection bag connected to said third mixing chamber; and xi) connection tubings interconnecting said bags, pumps, mixing chambers and collection bag; b. preparing respective solutions of a group of reagents including a protein, an alcohol, a cross-linking agent and a medicine, and i) filling said protein bag with a prepared solution of said protein; ii) filling said alcohol agent bag with a prepared solution of said alcohol; iii) filling said cross-linking agent bag with a prepared solution of said cross-linking agent; and iv) filling said medicine bag with a prepared solution of said medicine; c. setting respective pump rates of said pumps for mixing pre-determined amounts of said reagents; d. activating said pumps in sequence for mixing said reagents in a predetermined order within a pre-determined time period to produce said product, including: i) activating said protein pump to send said solution of said protein from said protein bag to said first mixing chamber, then activating said alcohol pump to send said solution of said alcohol from said alcohol bag to said first mixing chamber, to thereby mix therein said solution of said protein with said solution of said alcohol, resulting in a solution containing protein microspheres; ii) after a first delay period determined by said first delay means, activating said cross-linking agent pump to send said solution of said cross-linking agent from said cross-linking agent bag to said second mixing chamber, to thereby mix therein said solution of protein microspheres with said solution of said cross-linking agent, resulting in a solution of cross-linked protein microspheres; and iii) after a second delay period determined by said delay means, activating said medicine pump to send said solution of said medicine from said medicine bag to said third mixing chamber, to thereby mix therein said solution of cross-linked protein microspheres with said solution of said medicine, resulting in said product which is a solution of medicine-coated cross-linked protein microspheres; and e. collecting said product in said product collection bag; f. whereby said large scale production method produces said product of medicine coated cross-linked protein microspheres which are useful as in vivo medicine carriers for medicine administration. 13. The method as defined in claim 12 further including the step of sterilizing said large scale production system before using it to produce said product. 14. The method as defined in claim 12 further including the step of rinsing said large scale production system before using it to produce said product. 15. The method as defined in claim 12 further including the step of mixing a solution of post-treatment agent to said solution of medicine-coated cross-linked protein microspheres for post-production stabilization. 16. The method as defined in claim 12 further including the step of rinsing said large scale production system after using it to produce said product. 17. The method as defined in claim 12 wherein said protein is selected from a group including albumin and hemoglobin. 18. The method as defined in claim 12 wherein said alcohol is ethanol. 19. The method as defined in claim 12 wherein said cross-linking agent is selected from a group consisting of glutaraldehyde, glutathione, sodium sulfite, sodium bisulfite, nicotinamide adenine dinucleotide phosphate, dithiothreitol, polyethylene glycol, 2-mercaptoethanol, 1-ketoglutaric acid, gamma-aminolevulinic acid, N-acetylneuraminic acid, DL lactic acid, thioctic acid, succinic acid, ascorbic acid, stannous chloride, manganese chloride, magnesium chloride, gentamycin, poly-l-lysine, cysteine and dimethyl sulfoxide. 20. The method as defined in claim 12 wherein said medicine is fibrinogen. 21. The method as defined in claim 15 wherein said post-treatment agent is dextrose. 22. A device produced by the method as defined in claim 12. 23. A method for large scale production of a product of in vivo carriers, comprising the steps of: a. assembling a large scale production system including: i) a protein unit including a protein bag and a protein pump connected downstream from said protein bag; ii) an alcohol unit including an alcohol bag and an alcohol pump connected downstream from said alcohol bag; iii) a cross-linking agent unit including a cross-linking agent bag and a cross-linking agent pump connected downstream from said cross-linking agent bag; iv) a first mixing chamber connected downstream from said protein and alcohol pumps; v) a second mixing chamber connected downstream from said cross-linking agent pump and said first mixing chamber; vi) a product collection bag connected to said third mixing chamber; and vii) connection tubings interconnecting said bags, pumps, mixing chambers and collection bag; b. preparing respective solutions of a group of reagents including a protein, an alcohol and a cross-linking agent, and i) filling said protein bag with a prepared solution of said protein; ii) filling said alcohol agent bag with a prepared solution of said alcohol; and iii) filling said cross-linking agent bag with a prepared solution of said cross-linking agent; c. setting respective pump rates of said pumps for mixing pre-determined amounts of said reagents; d. activating said pumps in sequence for mixing said reagents in a predetermined order within a pre-determined time period to produce said product, including: i) activating said protein pump to send said solution of said protein from said protein bag to said first mixing chamber, then activating said alcohol pump to send said solution of said alcohol from said alcohol bag to said first mixing chamber, to thereby mix therein said solution of said protein with said solution of said alcohol, resulting in a solution containing protein spheres; and ii) activating said cross-linking agent pump to send said solution of said cross-linking agent from said cross-linking agent bag to said second mixing chamber, to thereby mix therein said solution of protein spheres with said solution of said cross-linking agent, resulting in a solution of cross-linked protein spheres; and e. collecting said product in said product collection bag; f. whereby said large scale production method produces said product of cross-linked protein spheres which are useful as in vivo carriers. 24. The method as defined in claim 23 further including the step of sterilizing said large scale production system before using it to produce said product. 25. The method as defined in claim 23 further including the step of rinsing said large scale production system before using it to produce said product. 26. The method as defined in claim 23 further including the step of mixing a solution of medicine for producing a solution of cross-linked protein spheres carrying medicine. 27. The method as defined in claim 26 wherein said solution of medicine is mixed with said solution of protein. 28. The method as defined in claim 26 wherein said solution of medicine is mixed with said solution of protein spheres. 29. The method as defined in claim 26 wherein said solution of medicine is mixed with said solution of cross-linked protein spheres. 30. The method as defined in claim 23 further including the step of mixing a solution of post-treatment agent to said solution of cross-linked protein spheres for post-production stabilization. 31. The method as defined in claim 23 further including the step of rinsing said large scale production system after using it to produce said product. 32. The method as defined in claim 23 wherein said protein is selected from a group including albumin and hemoglobin. 33. The method as defined in 23 wherein said alcohol is ethanol. 34. The method as defined in claim 23 wherein said cross-linking agent is selected from a group consisting of glutaraldehyde, glutathione, sodium sulfite, sodium bisulfite, nicotinamide adenine dinucleotide phosphate, dithiothreitol, polyethylene glycol, 2-mercaptoethanol, 1-ketoglutaric acid, gamma-aminolevulinic acid, N-acetylneuraminic acid, DL lactic acid, thioctic acid, succinic acid, ascorbic acid, stannous chloride, manganese chloride, magnesium chloride, gentamycin, poly-l-lysine, cysteine and dimethyl sulfoxide. 35. The method as defined in claim 26 wherein said medicine is fibrinogen. 36. The method as defined in claim 30 wherein said post-treatment agent is dextrose. 37. A device produced by the method as defined in claim 23. 38. An apparatus for large scale production of a product of in vivo medicine carriers for medicine administration, comprising: a. a large scale production system including: i) a protein unit including a protein bag and a protein pump connected downstream from said protein bag; ii) an alcohol unit including an alcohol bag and an alcohol pump connected downstream from said alcohol bag; and iii) a cross-linking agent unit including a cross-linking agent bag and a cross-linking agent pump connected downstream from said cross-linking agent bag; iv) a first mixing chamber connected downstream from said protein and alcohol pumps; v) a second mixing chamber connected downstream from said cross-linking agent pump and said first mixing chamber; vi) a product collection bag connected to said medicine mixing chamber for collecting said product; and vii) connection tubings interconnecting said bags, pumps, mixing chambers and collection bag; b. said bags filled with respective solutions of a group of reagents including a protein, an alcohol, and a cross-linking agent, where i) said protein bag is filled with a prepared solution of said protein; ii) said alcohol bag is filled with a prepared solution of said alcohol; and iii) said cross-linking agent bag is filled with a prepared solution of said cross-linking agent; c. said pumps set at respective pump rates for mixing pre-determined amounts of said reagents; d. said pumps activated in sequence for mixing said reagents in a predetemined order within a pre-determined time period to produce said product, where i) said protein pump is activated to send said solution of said protein from said protein bag to said first mixing chamber, then said alcohol pump is activated to send said solution of said alcohol from said alcohol bag to said first mixing chamber, to thereby mix therein said solution of said protein with said solution of said alcohol, resulting in a solution containing protein spheres; and ii) said cross-linking agent pump is activated to send said solution of said cross-linking agent from said cross-linking agent bag to said second mixing chamber, to thereby mix therein said solution of protein spheres with said solution of said cross-linking agent, resulting in said product which is a solution of cross-linked protein spheres; e. whereby said large seal production apparatus produces said product of medicine coated cross-linked protein microspheres which are useful as in vivo medicine carriers for medicine administration. 39. The apparatus as defined in claim 38 wherein said mixing chambers each has two inlet nozzles arranged 180 degrees opposite to each other to enhance the mixing. 40. The apparatus as defined in claim 38 wherein said mixing chambers are static mixers. 41. The method as defined in claim 38 further comprising means for sterilizing said large scale production system before using it to produce said product. 42. The method as defined in claim 38 further comprising means for rinsing said large scale production system before using it to produce said product. 43. The apparatus as defined in claim 38 further comprising means for mixing a solution of medicine to said solution of said protein for producing a solution of stabilized protein spheres carrying medicine. 44. The apparatus as defined in claim 38 further comprising means for mixing a solution of medicine to said solution of protein spheres for producing a solution of stabilized protein spheres carrying medicine. 45. The apparatus as defined in claim 38 further comprising means for mixing a solution of medicine to said solution of stabilized protein spheres for producing a solution of stabilized protein spheres carrying medicine. 46. The apparatus as defined in claim 38 further comprising means for mixing a solution of post-treatment agent to said solution of stabilized protein spheres for post-production stabilization. 47. The apparatus as defined in claim 38 further comprising means for rinsing said large scale production system after using it to produce said product.

Details for Patent 5,716,643

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2040-01-28
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2040-01-28